Piper Jaffray analyst, Edward Tenthoff, cut his Alnylam Pharmaceuticals (NASDAQ: ALNY) price target to $102 from $184 which still represents ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Leerink Partners Cut Price Target on Alnylam Pharma (ALNY) to $120 Following 4Q Earnings February 16, 2016 8:42 AM Alnylam Pharma (ALNY) Misses Q4 EPS by 11cFebruary 11, 2016 4:15 PM Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period ProgressFebruary 11, 2016 4:00 PM